ClinicalTrials.gg
DrugRead study by study

Daraxonrasib clinical trials

Also written RMC-6236.

Its developmentBy Revolution Medicines, step by step10 company-led studies, furthest phase 3: when each phase was reached, its deals, target and what is ahead.
studies test it
14
open now
13
in phase 3
5
first study started
2022
ClinicalTrials.gov finds 16 studies for daraxonrasib. How that becomes 14 hereChecked on ClinicalTrials.gov

Every study that search finds has been read, to see whether and how it gives daraxonrasib. Its counts are asked again every night. How drug pages count

  1. 16Found by its intervention search · See all 16 hereIt also reads titles, arm labels, keywords and descriptions, and counts the drug’s other names. Of these, 14 name it in an intervention entry. The counts it shows beside each synonym overlap: a study writing two names counts under both.
  2. +6Give it under a name that search misses: a biosimilar’s code or a misspelling
  3. 22Give daraxonrasib to participants
  4. −1Observe patients on it, or give it outside a trial
  5. −7Give it beside what is tested
  6. 14Test it: the count on this site

Get an email when these change. Save the daraxonrasib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
26 Aug 2026 · RASONQUE · NDA 220910 (FDA, Drugs@FDA)
European Union
Not in EMA's list of EU-wide authorizations

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Daraxonrasib
10

Development codes

RMC-6236
8

Studies by the year they started

11 studies that test it; most in 2026 (4); 3 more planned to start later

Studies that test daraxonrasib, by start year
YearStudies
20221
20231
20243
20252
20264

By phase

A phase 1/2 study counts in both.

Phase 1
7
Phase 2
8
Phase 3
5

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 10 · Other 4

Revolution Medicines, Inc. (10) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (1) · National Health Research Institutes, Taiwan (1) · Dana-Farber Cancer Institute (1) · Children's Oncology Group (1)

Often tested with

Tested in the same studies.

Zoldonrasib (3) · Gemcitabine (2) · Albumin-Bound Paclitaxel (2) · Paclitaxel (2) · Elironrasib (2) · Cetuximab (1)

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

New treatments tested with it · 4 most studied

New when their studies opened, with daraxonrasib beside them; studies of each.

Reaching primary completion within a year · 2

Studies that test daraxonrasib.

Studies

Open first, then newest update. How each study uses daraxonrasib has had a first review, but it may not be perfect: check the study record before relying on it for anything important, and report a problem from its row. Some give it without naming it in an intervention entry: those were found by reading the record.

Testing it · 14

Behind its US label · 1 — the studies the FDA label of RASONQUE describes

From the Clinical Studies section of RASONQUE (2026-08), as openFDA has it. A study the site does not hold is left out.

Tested on its own · 7 — no other medicine in its arm
Tested with established drugs · 2 — they are given beside it
Tested in a combination · 5 — another drug in the study is under test too
Beside a new treatment under test · 6 — a new drug, cell therapy or vaccine is what the study tests

New treatments tested with daraxonrasib: navlimetostat 1 · PARP1 Inhibitor SNV1521 1 · KRAS G12V Inhibitor RMC-5127 1 · zoldonrasib 1

Beside supportive care · 1 — a supportive treatment or test is studied
Observed · 1 — patients on it are followed, or it is given outside a trial

What changed recently

From the registry's own updates since Oct 20, 2026.

Newly registered2

Codes

What other systems call daraxonrasib · ClinicalTrials.gg INT002100

  • MeSH (NLM) C000731071daraxonrasibOne source NLM
  • UNII (FDA) B6T47Y2UAPDARAXONRASIBConfirmed FDA, NLM, Wikidata
  • Wikidata Q136659312daraxonrasibConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C188048DaraxonrasibOne source FDA

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.

Start the discussion